Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective studyResearch in context

Summary: Background: Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-year overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have prolonged OS. Pancreatic metastases are uncommon overall, with mRCC being the most common etiology of pancrea...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Cassandra Duarte, Junxiao Hu, Benoit Beuselinck, Justine Panian, Nicole Weise, Nazli Dizman, Katharine A. Collier, Nityam Rathi, Haoran Li, Roy Elias, Nieves Martinez-Chanza, Tracy L. Rose, Lauren C. Harshman, Dharmesh Gopalakrishnan, Ulka Vaishampayan, Yousef Zakharia, Vivek Narayan, Benedito A. Carneiro, Anthony Mega, Nirmish Singla, Cheryl Meguid, Saby George, James Brugarolas, Neeraj Agarwal, Amir Mortazavi, Sumanta Pal, Rana R. McKay, Elaine T. Lam
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2023-06-01
coleção:	EClinicalMedicine
Assuntos:	Metastatic renal cell carcinoma Pancreatic metastases VEGFR Immunotherapy
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2589537023001955
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!